Online inquiry

IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10140MR)

This product GTTS-WQ10140MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CALCA&CALCB gene. The antibody can be applied in Migraine research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10140MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6604MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA DC-1728001
GTTS-WQ5896MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CIM 331
GTTS-WQ13975MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ4830MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BT-061
GTTS-WQ2751MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG162
GTTS-WQ1027MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-399
GTTS-WQ12490MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NN-8226
GTTS-WQ11709MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MILR1444A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW